{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glargine+and+aspart", "query": { "intervention": "glargine and aspart" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glargine+and+aspart&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T18:42:58.569Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02420262", "title": "A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/liraglutide", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 506, "start_date": "2015-07-26", "completion_date": "2016-10-05", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 50, "location_summary": "Tuscumbia, Alabama • Anaheim, California • Bermuda Dunes, California + 44 more", "locations": [ { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bermuda Dunes", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420262" }, { "nct_id": "NCT03260868", "title": "Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine, 300 units per milliliter (U/mL)", "type": "DRUG" }, { "name": "Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-09-19", "completion_date": "2018-11-22", "has_results": true, "last_update_posted_date": "2022-04-07", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 3, "location_summary": "West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia", "locations": [ { "city": "West Des Moines", "state": "Iowa" }, { "city": "Houston", "state": "Texas" }, { "city": "Bridgeport", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03260868" }, { "nct_id": "NCT00309244", "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Type 2" ], "interventions": [ { "name": "Technosphere® Insulin Inhalation Powder", "type": "DRUG" }, { "name": "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 677, "start_date": "2006-02", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2014-10-16", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 80, "location_summary": "Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309244" }, { "nct_id": "NCT01045447", "title": "Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/insulin aspart", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 465, "start_date": "2010-01", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 24, "location_summary": "Fresno, California • Waterbury, Connecticut • Boynton Beach, Florida + 19 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01045447" }, { "nct_id": "NCT04880850", "title": "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin icodec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 582, "start_date": "2021-05-14", "completion_date": "2022-06-16", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 52, "location_summary": "Little Rock, Arkansas • Anaheim, California • Concord, California + 44 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04880850" }, { "nct_id": "NCT04416269", "title": "Oral Anti Diabetic Agents in the Hospital", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Oral Anti-diabetes Drugs alone", "type": "DRUG" }, { "name": "Basal bolus insulin", "type": "DRUG" }, { "name": "Supplemental insulin", "type": "DRUG" }, { "name": "Continuous glucose monitoring (CGM)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 85, "start_date": "2020-08-07", "completion_date": "2025-04-11", "has_results": true, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416269" }, { "nct_id": "NCT00417989", "title": "Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "MiniMed Paradigm REAL-Time System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic MiniMed, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "7 Years to 70 Years" }, "enrollment_count": 485, "start_date": "2007-01", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2018-05-23", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 26, "location_summary": "La Jolla, California • Orange, California • Boulder, Colorado + 23 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00417989" }, { "nct_id": "NCT01819129", "title": "Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Faster-acting insulin aspart", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 881, "start_date": "2013-09-09", "completion_date": "2015-01-22", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 77, "location_summary": "Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01819129" }, { "nct_id": "NCT02518945", "title": "Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Dapagliflozin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 26, "start_date": "2015-08", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02518945" }, { "nct_id": "NCT01524705", "title": "FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Prandial insulin", "type": "DRUG" }, { "name": "Exenatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 102, "start_date": "2012-08", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-09-24T18:42:58.569Z", "location_count": 12, "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01524705" } ] }